---
layout: default
title: Inclisiran
description: "Inclisiran 的老藥新用潛力分析。模型預測等級 L5，包含 10 個預測適應症。查看 AI 預測與臨床證據完整報告。"
parent: 僅模型預測 (L5)
nav_order: 86
evidence_level: L1
indication_count: 10
---

# Inclisiran

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
證據等級: <strong>L5</strong> | 預測適應症: <strong>10</strong> 個
</p>

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Inclisiran：從高膽固醇血症到 Potassium Deficiency Disease

## 一句話總結

<p class="key-answer" data-question="Inclisiran 可以用於治療什麼新適應症？">
Inclisiran 原本用於原發性高血脂症的 LDL-C 降低治療。
TxGNN 模型預測它可能對 **Potassium Deficiency Disease** 有效，
但目前缺乏臨床試驗和文獻支持這個方向。
</p>


## 快速總覽

| 項目 | 內容 |
|------|------|
| 原適應症 | 原發性高血脂症(含異合子家族性高膽固醇血症)之 LDL-C 降低 |
| 預測新適應症 | potassium deficiency disease、esophageal disease、atypical coarctation of aorta、migraine disorder、non-syndromic esophageal malformation、migraine with brainstem aura、migraine with or without aura, susceptibility to、aortic malformation、esophageal ulcer、Raynaud disease |
| TxGNN 預測分數 | 99.93% |
| 證據等級 | L5 |
| 台灣上市 | 已上市 |
| 許可證數 | 1 張(3筆重複記錄) |
| 建議決策 | Hold |






## 預測適應症詳細分析

<details class="indication-section" open>
<summary>
<span class="indication-name">1. potassium deficiency disease</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.93%</span> <span class="primary-badge">主要分析</span>
</summary>
<div class="indication-content">

<h3>為什麼這個預測合理？</h3>

<p>Inclisiran 是一種小干擾 RNA (siRNA) 藥物，透過抑制肝臟中 PCSK9 蛋白的合成來增加 LDL 受體的表現，進而降低血液中的 LDL 膽固醇濃度。</p>

<p>與鉀缺乏症的關聯目前缺乏明確的機轉解釋：</p>
<ol>
<li>Inclisiran 的主要作用靶點為 PCSK9，與鉀代謝無直接關聯</li>
<li>目前沒有臨床或臨床前研究探討 Inclisiran 對鉀代謝的影響</li>
<li>此預測可能源於知識圖譜中的間接關聯，需要進一步驗證</li>
</ol>

<h3>臨床試驗</h3>

<p>目前無針對此特定適應症的臨床試驗登記。</p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. esophageal disease</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.87%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. atypical coarctation of aorta</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.86%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. migraine disorder</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.83%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. non-syndromic esophageal malformation</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.83%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. migraine with brainstem aura</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.78%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. migraine with or without aura, susceptibility to</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.78%</span>
</summary>
<div class="indication-content">

<h3>相關文獻（20 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22938964/" target="_blank">22938964</a></td><td>2012</td><td>Article</td><td>Handbook of clinical neurology</td><td>Animal models.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16201993/" target="_blank">16201993</a></td><td>2005</td><td>Article</td><td>Epilepsia</td><td>Rearranging receptors.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22266888/" target="_blank">22266888</a></td><td>2011</td><td>Article</td><td>Seminars in neurology</td><td>Genetics of epilepsy.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34575901/" target="_blank">34575901</a></td><td>2021</td><td>Article</td><td>International journal of molec</td><td>Selected Molecular Targets for Antiepileptogenesis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34209535/" target="_blank">34209535</a></td><td>2021</td><td>Article</td><td>International journal of molec</td><td>Neuroinflammation: A Signature or a Cause of Epilepsy?</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/17460155/" target="_blank">17460155</a></td><td>2007</td><td>Article</td><td>Neurology</td><td>Familial occipitotemporal lobe epilepsy and migraine with visual aura: linkage t...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30267335/" target="_blank">30267335</a></td><td>2018</td><td>Article</td><td>Neurological sciences : offici</td><td>Methylenetetrahydrofolate reductase C677T polymorphism and susceptibility to epi...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/23294289/" target="_blank">23294289</a></td><td>2013</td><td>Article</td><td>Epilepsia</td><td>Evidence for a shared genetic susceptibility to migraine and epilepsy.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32639997/" target="_blank">32639997</a></td><td>2020</td><td>Article</td><td>PLoS neglected tropical diseas</td><td>Protection or susceptibility to devastating childhood epilepsy: Nodding Syndrome...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28086980/" target="_blank">28086980</a></td><td>2017</td><td>Article</td><td>Journal of neuroinflammation</td><td>Inflammation in epileptogenesis after traumatic brain injury.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33856647/" target="_blank">33856647</a></td><td>2021</td><td>Article</td><td>Molecular neurobiology</td><td>Epilepsy and Migraine Shared Genetic and Molecular Mechanisms: Focus on Therapeu...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21269290/" target="_blank">21269290</a></td><td>2011</td><td>Article</td><td>Epilepsia</td><td>Epilepsy and the new cytogenetics.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/19935934/" target="_blank">19935934</a></td><td>2009</td><td>Article</td><td>Tidsskrift for den Norske laeg</td><td>[Psychogenic non-epileptic seizures].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24874544/" target="_blank">24874544</a></td><td>2014</td><td>Article</td><td>Neurobiology of disease</td><td>Does gender influence susceptibility and consequences of acquired epilepsies?</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28837072/" target="_blank">28837072</a></td><td>2017</td><td>Article</td><td>International journal of molec</td><td>Understanding the Epilepsy in POLG Related Disease.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16377142/" target="_blank">16377142</a></td><td>2006</td><td>Article</td><td>Epilepsy research</td><td>Pediatric epilepsy models.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32521797/" target="_blank">32521797</a></td><td>2020</td><td>Article</td><td>International journal of molec</td><td>Reactive Glia Inflammatory Signaling Pathways and Epilepsy.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24643875/" target="_blank">24643875</a></td><td>2015</td><td>Article</td><td>Metabolic brain disease</td><td>Does abnormal glycogen structure contribute to increased susceptibility to seizu...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21919606/" target="_blank">21919606</a></td><td>2011</td><td>Article</td><td>Pharmacogenomics</td><td>Pharmacogenomics of the human µ-opioid receptor.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12183340/" target="_blank">12183340</a></td><td>2002</td><td>Article</td><td>Brain : a journal of neurology</td><td>Disease modification in partial epilepsy.</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. aortic malformation</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.76%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（2 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06597006" target="_blank">NCT06597006</a></td><td>PHASE3</td><td>RECRUITING</td><td>9</td><td>Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06597019" target="_blank">NCT06597019</a></td><td>PHASE3</td><td>RECRUITING</td><td>51</td><td>Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. esophageal ulcer</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.73%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. Raynaud disease</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.73%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>


## 台灣上市資訊

| 許可證號 | 品名 | 劑型 | 核准適應症 |
|---------|------|------|-----------|
| 衛部藥輸字第028761號 | 樂脂益注射劑 | 注射液劑 | 原發性高血脂症(含異合子家族性高膽固醇血症)作為飲食及降血脂藥品的輔助治療 |

## 安全性考量

- **藥物交互作用**：目前 DDI 資料庫中未發現顯著交互作用

- **已知副作用**：注射部位反應、上呼吸道感染、肌肉骨骼疼痛

## 結論與下一步

**決策：Hold**

**理由：**
Inclisiran 用於鉀缺乏症的預測缺乏明確的機轉支持和臨床證據。目前無任何臨床試驗或文獻探討此關聯性。

**若要推進需要：**
- 進行機轉層面的研究，探討 PCSK9 抑制與鉀代謝的潛在關聯
- 分析 Inclisiran 臨床試驗中的電解質變化數據
- 建立假說並設計探索性臨床研究


---

## 相關藥物報告

- [Cyclizine]({{ "/drugs/cyclizine/" | relative_url }}) - 證據等級 L5
- [Methocarbamol]({{ "/drugs/methocarbamol/" | relative_url }}) - 證據等級 L5
- [Oxytetracycline]({{ "/drugs/oxytetracycline/" | relative_url }}) - 證據等級 L5
- [Pipemidic Acid]({{ "/drugs/pipemidic_acid/" | relative_url }}) - 證據等級 L5
- [Insulin Lispro]({{ "/drugs/insulin_lispro/" | relative_url }}) - 證據等級 L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## 引用本報告

如需引用本報告，請使用以下格式：

**APA 格式：**
```
TwTxGNN. (2026). Inclisiran老藥新用驗證報告. https://twtxgnn.yao.care/drugs/inclisiran/
```

**BibTeX 格式：**
```bibtex
@misc{twtxgnn_inclisiran,
  title = {Inclisiran老藥新用驗證報告},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/inclisiran/}
}
```

---

<div class="disclaimer">
<strong>免責聲明</strong><br>
本報告僅供學術研究參考，<strong>不構成醫療建議</strong>。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
<br><br>
<small>最後審核：2026-02-20 | 審核者：TwTxGNN Research Team</small>
</div>

{% include giscus.html %}
